<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02774850</url>
  </required_header>
  <id_info>
    <org_study_id>15-012074</org_study_id>
    <nct_id>NCT02774850</nct_id>
  </id_info>
  <brief_title>Home Away From Home - Medical Outcomes</brief_title>
  <acronym>Aim 1</acronym>
  <official_title>Home or Away From Home: Comparing Clinical Outcomes Relevant to the Care of Pediatric Acute Myeloid Leukemia During Periods of Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>C.S. Mott Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Healthcare of Atlanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Medical Center Dallas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arkansas Children's Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lucile Packard Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Primary Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rady Children's Hospital, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alfred I. duPont Hospital for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens
      that result in periods of profound neutropenia leaving patients susceptible to severe
      infectious complications. Infectious complications are the leading cause of treatment related
      mortality among AML patients, but there are little clinical data to inform whether management
      of neutropenia post AML chemotherapy should occur in an outpatient or inpatient setting. The
      primary objective of this study is to compare the clinical effectiveness of outpatient versus
      inpatient management of neutropenia in children with AML.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a bidirectional observational cohort study.

      Participants will be patients 18 years of age or younger at diagnosis receiving or having
      received chemotherapy for AML from fifteen participating pediatric hospitals across the
      United States. There is no study intervention; this is a medical record abstraction study
      only. Investigators will abstract subjects medical record data over the study period in order
      to study clinical outcomes including the occurrence of bacteremia and time to the start of
      the next course in the chemotherapy regimen, in relation to neutropenia management strategy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of post-chemotherapy bacteremia</measure>
    <time_frame>January 1, 2012 to December 31, 2018</time_frame>
    <description>Identification of bacteremia will begin three days after completion of a chemotherapy course and will continue until recovery of absolute neutrophil count (ANC &gt; 500 uL), or until the start of the next course (for a very small number of patients who begin the next course of chemotherapy prior to count recovery). Bacteremia will be defined as a single positive blood culture for a bacterial pathogen (including Viridans group Streptococci). If the bacterium is an organism considered as a common commensal organism by the National Healthcare Safety Network, two separate positive blood cultures will be required for classification as bacteremia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the initiation of the next chemotherapy course</measure>
    <time_frame>January 1, 2012 to December 31, 2018</time_frame>
    <description>Time to next course of chemotherapy will be measured as the number of days from the three days after the completion chemotherapy in a given course until the first day of the next course.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Neutropenia</condition>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>Early Discharge Management</arm_group_label>
    <description>Discharge to outpatient management during neutropenia within 3 days after chemotherapy completion in a given course</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inpatient Management</arm_group_label>
    <description>Remain hospitalized during chemotherapy-induced neutropenia</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include all AML patients who received or will receive
        chemotherapy between January 1, 2012 and December 31, 2018 at any of the fifteen
        participating pediatric institutions across the US. Patients discharged within 3 days after
        completion of that chemotherapy course will be categorized as 'early discharge' to
        outpatient management during neutropenia. Patients meeting eligibility criteria for 'early
        discharge' but remaining in the hospital more than 3 days after completion of that
        chemotherapy course will be categorized as inpatient management. Patients will be
        considered early discharge-eligible if there is no evidence of fever, infection or
        intensive care unit (ICU) level care within Â± 3 days of the last dose of chemotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females 18 years of age or younger at diagnosis.

          2. Receipt or planned receipt of AML chemotherapy between January 1, 2012 and December
             31, 2018.

        Exclusion Criteria:

          1. Patients being treated for relapsed AML

          2. Patients with Acute Promyelocytic Leukemia (APML)

          3. Patients undergoing stem cell transplant (SCT)

          4. Patients receiving reduced intensity frontline chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Aplenc, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Aplenc, MD, PhD</last_name>
    <email>aplenc@chop.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Mian, MD</last_name>
      <email>mianamir@uams.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Aftandilian, MD</last_name>
      <email>aftandil@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Yu, MD</last_name>
      <email>jyu@rchsd.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Maloney, MD</last_name>
      <email>Kelly.Maloney@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred I DuPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emi Caywood, MD</last_name>
      <email>emi.caywood@nemours.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staci Arnold, MD</last_name>
      <email>staci.denise.arnold@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuko Hijiya, MD</last_name>
      <email>NHijiya@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Lotterman, MD</last_name>
      <email>clotterman@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajen Mody, MD</last_name>
      <email>rmody@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meret Henry, MD</last_name>
      <email>mhenry@med.wayne.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anderson Collier, MD</last_name>
      <email>acollier@umc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Aplenc, MD, PhD</last_name>
      <phone>267-426-7252</phone>
      <email>APLENC@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brian Fisher, DO, MPH, MSCE</last_name>
      <phone>267-426-0196</phone>
      <email>FISHERBRIA@email.chop.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Winick, MD</last_name>
      <email>naomi.winick@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gramatges, MD</last_name>
      <email>mmgramat@txch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Raetz, MD</last_name>
      <email>Elizabeth.Raetz@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Wilkes, MD</last_name>
      <email>WILKESJ@email.chop.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2016</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Neutropenia Management</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Chart Abstraction</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Coded, limited data sets will be shared with participating sites upon approved request. Only aggregate level data will be shared with the study sponsor Patient-Centered Outcomes Research Institute (PCORI).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

